User profiles for Aziz Nazha
 | Aziz NazhaLerner College of Medicine/Case Western Reserve University Verified email at ccf.org Cited by 5859 |
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
…, G Garcia-Manero, S Faderl, A Nazha… - Blood, The Journal …, 2013 - ashpublications.org
Patients received 5-azacytidine (AZA) 75 mg/m 2 intravenously daily for 7 days and sorafenib
400 mg orally twice daily continuously; cycles were repeated at ∼1-month intervals. Forty-…
400 mg orally twice daily continuously; cycles were repeated at ∼1-month intervals. Forty-…
[HTML][HTML] Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic …
…, CD Bloomfield, A Moseley, A Nazha… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
… Sekeres, Megan Othus, Diane Roulston, Aziz Nazha, Mario R. Velasco, Rakesh Gaur,
Eyal C. Attar, Elina K. … Sekeres, Megan Othus, Diane Roulston, Anna Moseley, Aziz Nazha …
Eyal C. Attar, Elina K. … Sekeres, Megan Othus, Diane Roulston, Anna Moseley, Aziz Nazha …
[HTML][HTML] TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS).
Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic …
Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic …
Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
…, H Kantarjian, F Ravandi, A Nazha… - American journal of …, 2015 - Wiley Online Library
We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute
myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received …
myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received …
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Early responses to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)-chronic
phase (CP) are associated with improved outcome. We analyzed the impact of such a …
phase (CP) are associated with improved outcome. We analyzed the impact of such a …
[PDF][PDF] hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies
…, LR Pageon, M McArthur, A Multani, A Nazha… - Cancer cell, 2015 - cell.com
hnRNP K regulates cellular programs, and changes in its expression and mutational status
have been implicated in neoplastic malignancies. To directly examine its role in …
have been implicated in neoplastic malignancies. To directly examine its role in …
Machine learning in haematological malignancies
Machine learning is a branch of computer science and statistics that generates predictive or
descriptive models by learning from training data rather than by being rigidly programmed. It …
descriptive models by learning from training data rather than by being rigidly programmed. It …
[HTML][HTML] Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer
…, D Angelini, M Kalaycio, A Nazha… - Journal of clinical …, 2018 - ncbi.nlm.nih.gov
Purpose To investigate the risk and outcomes of second hematologic malignancies (SHMs)
in a population-based cohort of patients with well-differentiated thyroid cancer (WDTC) …
in a population-based cohort of patients with well-differentiated thyroid cancer (WDTC) …
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
…, U Germing, EK Ritchie, V Verma, A Nazha… - Blood …, 2018 - ashpublications.org
Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are
limited by small numbers and their single-center nature, and report conflicting data regarding …
limited by small numbers and their single-center nature, and report conflicting data regarding …
[HTML][HTML] Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells
TET2 is a dioxygenase that catalyses multiple steps of 5-methylcytosine oxidation. Although
TET2 mutations frequently occur in various types of haematological malignancies, the …
TET2 mutations frequently occur in various types of haematological malignancies, the …
